Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL370208 | 0.90 | GPBAR1 (0.46) | EPHX2BRD4GPBAR1SLC6A9LMNA | |
| SCHEMBL1390123 | 0.90 | GPBAR1 (0.46) | EPHX2BRD4GPBAR1SLC6A9LMNA | |
| SCHEMBL1390120 | 0.90 | GPBAR1 (0.46) | EPHX2BRD4GPBAR1SLC6A9LMNA | |
| SCHEMBL1390430 | 0.89 | EPHX2 (0.40) | EPHX2BRD4GPBAR1SLC6A9LMNA | |
| SCHEMBL1390296 | 0.88 | GPBAR1 (0.40) | EPHX2BRD4GPBAR1SLC6A9LMNA | |
| SCHEMBL1390381 | 0.88 | GCGR (0.43) | EPHX2BRD4GPBAR1 | |
| SCHEMBL368212 | 0.88 | TP53 (0.36) | EPHX2BRD4LMNAPOLB | |
| SCHEMBL1390386 | 0.86 | MAPK1 (0.40) | EPHX2BRD4GPBAR1SLC6A9LMNA | |
| SCHEMBL1390429 | 0.86 | SLC6A9 (0.43) | EPHX2BRD4GPBAR1SLC6A9 | |
| SCHEMBL1390170 | 0.84 | EPHX2 (0.42) | EPHX2BRD4GPBAR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | EPHX2 1909/4885BRD4 3540/4885GPBAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.